S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NYSE:TEVA

Teva Pharmaceutical Industries Stock Forecast, Price & News

$8.95
-0.10 (-1.10 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.90
$9.05
50-Day Range
$8.38
$10.18
52-Week Range
$8.24
$13.30
Volume5.40 million shs
Average Volume8.85 million shs
Market Capitalization$9.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44
30 days | 90 days | 365 days | Advanced Chart
Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.


Teva Pharmaceutical Industries logo

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

308th out of 1,351 stocks

Pharmaceutical Preparations Industry

142nd out of 664 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

Is Teva Pharmaceutical Industries a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries
or view top-rated stocks.

What stocks does MarketBeat like better than Teva Pharmaceutical Industries?

Wall Street analysts have given Teva Pharmaceutical Industries a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Teva Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 28,530,000 shares, a drop of 14.2% from the July 29th total of 33,240,000 shares. Based on an average daily trading volume, of 9,030,000 shares, the short-interest ratio is currently 3.2 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Teva Pharmaceutical Industries
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Wednesday, July, 28th. The company reported $0.59 EPS for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.04. The company earned $3.91 billion during the quarter, compared to the consensus estimate of $4.03 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 23.88% and a negative net margin of 23.98%.
View Teva Pharmaceutical Industries' earnings history
.

How has Teva Pharmaceutical Industries' stock price been impacted by COVID-19?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TEVA stock has decreased by 0.7% and is now trading at $8.95.
View which stocks have been most impacted by COVID-19
.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share (EPS) guidance of $2.500-$2.700 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.450. The company issued revenue guidance of $16 billion-$16.40 billion, compared to the consensus revenue estimate of $16.55 billion.

What price target have analysts set for TEVA?

7 analysts have issued 12 month price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $11.33 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Kåre Schultz, President, Chief Executive Officer & Director
  • Eric Drapé, Executive Vice President-Global Operations
  • Eli Kalif, Chief Financial Officer & Executive Vice President
  • Hafrun Fridriksdottir, Executive VP-Global Research & Development
  • Lori A. Queisser, Senior Vice President & Global Compliance Officer

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Jefferies Group LLC (0.00%), BlackRock Inc. (3.64%), State Street Corp (1.50%), Susquehanna International Group LLP (0.00%), Capital International Investors (0.92%) and Harel Insurance Investments & Financial Services Ltd. (0.91%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Michael James Mcclellan, Pharmaceutical Co Ltd Takeda, Richard Daniell and Rosemary A Crane.
View institutional ownership trends for Teva Pharmaceutical Industries
.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Capital International Investors, Caisse DE Depot ET Placement DU Quebec, BlackRock Inc., First Light Asset Management LLC, Squarepoint Ops LLC, Millennium Management LLC, and Archon Partners LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Teva Pharmaceutical Industries
or view top insider-selling stocks.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Legal & General Group Plc, Bank of Montreal Can, Credit Suisse AG, Citadel Advisors LLC, Susquehanna International Group LLP, Renaissance Technologies LLC, and Deutsche Bank AG.
View insider buying and selling activity for Teva Pharmaceutical Industries
or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $8.95.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries has a market capitalization of $9.78 billion and generates $16.66 billion in revenue each year. The company earns $-3,990,000,000.00 in net income (profit) each year or $2.45 on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries employs 37,736 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Where are Teva Pharmaceutical Industries' headquarters?

Teva Pharmaceutical Industries is headquartered at 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at (723) 926-7267 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.